1
|
Development and Validation of a Diagnostic Nomogram for the Preoperative Differentiation Between Follicular Thyroid Carcinoma and Follicular Thyroid Adenomas. J Comput Assist Tomogr 2021; 45:128-134. [PMID: 33475318 DOI: 10.1097/rct.0000000000001078] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
OBJECTIVE The aim of the study was to construct and validate a nomogram for differentiating follicular thyroid carcinoma (FTC) from follicular thyroid adenoma (FTA). METHODS Two hundred patients with pathologically confirmed thyroid follicular neoplasms were retrospectively analyzed. The patients were randomly divided into a training set (n = 140) and validation set (n = 60). Baseline data including demographics, CT (computed tomography) signs, and radiomic features were analyzed. Predictive models were developed and compared to build a nomogram. The predictive effectiveness of it was evaluated by the area under receiver operating characteristic curve (AUC). RESULTS The CT model, radiomic model and combination model showed excellent discrimination (AUCs [95% confidence interval] = 0.847 [0.766-0.928], 0.863 [0.746-0.932], 0.913 [0.850-0.975]). The nomogram based on the combination model showed remarkable discrimination in the training and validation sets. The calibration curves suggested good consistency between actual observation and prediction. CONCLUSIONS This study proposed a nomogram that can accurately and intuitively predict the malignancy potential of follicular thyroid neoplasms.
Collapse
|
2
|
Zhang W, Sun W, Qin Y, Wu C, He L, Zhang T, Shao L, Zhang H, Zhang P. Knockdown of KDM1A suppresses tumour migration and invasion by epigenetically regulating the TIMP1/MMP9 pathway in papillary thyroid cancer. J Cell Mol Med 2019; 23:4933-4944. [PMID: 31211500 PMCID: PMC6653290 DOI: 10.1111/jcmm.14311] [Citation(s) in RCA: 27] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/23/2018] [Revised: 02/10/2019] [Accepted: 02/20/2019] [Indexed: 12/31/2022] Open
Abstract
Epigenetic dysregulation plays an important role in cancer. Histone demethylation is a well‐known mechanism of epigenetic regulation that promotes or inhibits tumourigenesis in various malignant tumours. However, the pathogenic role of histone demethylation modifiers in papillary thyroid cancer (PTC), which has a high incidence of early lymphatic metastasis, is largely unknown. Here, we detected the expression of common histone demethylation modifiers and found that the histone H3 lysine 4 (H3K4) and H3 lysine 9 (H3K9) demethylase KDM1A (or lysine demethylase 1A) is frequently overexpressed in PTC tissues and cell lines. High KDM1A expression correlated positively with age <55 years and lymph node metastasis in patients with PTC. Moreover, KDM1A was required for PTC cell migration and invasion. KDM1A knockdown inhibited the migration and invasive abilities of PTC cells both in vitro and in vivo. We also identified tissue inhibitor of metalloproteinase 1 (TIMP1) as a key KDM1A target gene. KDM1A activated matrix metalloproteinase 9 (MMP9) through epigenetic repression of TIMP1 expression by demethylating H3K4me2 at the TIMP1 promoter region. Rescue experiments clarified these findings. Altogether, we have uncovered a new mechanism of KDM1A repression of TIMP1 in PTC and suggest that KDM1A may be a promising therapeutic target in PTC.
Collapse
Affiliation(s)
- WenQian Zhang
- Department of Thyroid Surgery, The First Hospital of China Medical University, Shenyang Liaoning Province, China
| | - Wei Sun
- Department of Thyroid Surgery, The First Hospital of China Medical University, Shenyang Liaoning Province, China
| | - Yuan Qin
- Department of Thyroid Surgery, The First Hospital of China Medical University, Shenyang Liaoning Province, China
| | - CangHao Wu
- Department of Thyroid Surgery, The First Hospital of China Medical University, Shenyang Liaoning Province, China
| | - Liang He
- Department of Thyroid Surgery, The First Hospital of China Medical University, Shenyang Liaoning Province, China
| | - Ting Zhang
- Department of Thyroid Surgery, The First Hospital of China Medical University, Shenyang Liaoning Province, China
| | - Liang Shao
- Department of Thyroid Surgery, The First Hospital of China Medical University, Shenyang Liaoning Province, China
| | - Hao Zhang
- Department of Thyroid Surgery, The First Hospital of China Medical University, Shenyang Liaoning Province, China
| | - Ping Zhang
- Department of Thyroid Surgery, The First Hospital of China Medical University, Shenyang Liaoning Province, China
| |
Collapse
|
3
|
Pahk K, Choi S, Kim S. Functional visceral fat activity evaluated by preoperative F-18 FDG PET/CT predicts regional lymph node metastasis in differentiated thyroid cancer. Clin Endocrinol (Oxf) 2018; 88:963-968. [PMID: 29603322 DOI: 10.1111/cen.13604] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/28/2017] [Revised: 03/02/2018] [Accepted: 03/21/2018] [Indexed: 01/02/2023]
Abstract
OBJECTIVE We investigated the predictive role of functional visceral fat activity evaluated by preoperative F-18 FDG PET/CT for regional lymph node metastasis in patients with differentiated thyroid cancer. DESIGN AND PATIENTS Fifty-eight patients with newly diagnosed differentiated thyroid cancer were enrolled in this study, retrospectively (men 14; women 44; age 53 ± 14.5). They all received preoperative F-18 FDG PET/CT and surgery. Functional visceral fat activity was defined as maximum standardized uptake value (SUVmax) of visceral fat divided by SUVmax of subcutaneous fat (V/S ratio). Pathology results were confirmed through the surgical specimens. RESULTS The patients with regional lymph node metastasis showed higher functional visceral fat activity (V/S ratio) than the patients without regional lymph node metastasis (2.12 ± 0.6 vs 1.62 ± 0.34, P = .001). V/S ratio of 1.78 was suggested as an optimal cut-off value for predicting regional lymph node metastasis (sensitivity; 70.3%, specificity; 83.3%, area under the curve; 0.778, P < .0001). Furthermore, functional visceral fat activity was significantly associated with regional lymph node metastasis in patients with differentiated thyroid cancer by univariate and multivariate analyses. CONCLUSIONS Functional visceral fat activity significantly affects the regional lymph node metastasis status in patients with differentiated thyroid cancer. Furthermore, it may also be useful to predict regional lymph node metastasis.
Collapse
Affiliation(s)
- Kisoo Pahk
- Department of Nuclear Medicine, Korea University Anam Hospital, Seoul, Korea
| | - Sunju Choi
- Department of Nuclear Medicine, Korea University Anam Hospital, Seoul, Korea
| | - Sungeun Kim
- Department of Nuclear Medicine, Korea University Anam Hospital, Seoul, Korea
| |
Collapse
|
4
|
Cao CJ, Dou CY, Lian J, Luan ZS, Zhou W, Xie W, Chen L, Zhou K, Lai H. Clinical outcomes and associated factors of radioiodine-131 treatment in differentiated thyroid cancer with cervical lymph node metastasis. Oncol Lett 2018; 15:8141-8148. [PMID: 29740497 DOI: 10.3892/ol.2018.8270] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/25/2016] [Accepted: 11/29/2017] [Indexed: 01/26/2023] Open
Abstract
Cervical lymph node metastasis (CLNM) is common in differentiated thyroid cancer (DTC). Radioiodine-131 (131I) treatment is recommended for the removal of residual thyroid tissue following thyroidectomy. To date, the effect of 131I therapy on the outcomes of patients with DTC with CLNM is unclear. The aim of the present study was to evaluate the final outcome of patients with DTC with CLNM according to 131I administration, and to analyze the factors that may affect clinical outcomes. A total of 357 patients with DTC with CLNM were recruited and divided into three groups: Those who received 2, 3 or 4 doses of 131I therapy, respectively. Successful ablation was defined as levels of stimulated serum thyroglobulin <2 ng/ml in the absence of CLNM. The rates of successful ablation were 80.35 (229/285), 76.36 (42/55) and 70.59% (12/17) for patients who received 2, 3 and 4 doses, respectively. The patients with DTC with CLNM who were <45 years old, with tumor sizes <2 cm, solitary nodules and TNM stage I-II disease exhibited significantly higher rates of successful ablation compared with the patients who were ≥45 years old, with tumor size ≥2 cm, multiple nodules and stage III-IV disease. Multivariate analyses revealed that tumor size, number of nodules and TNM stage were independent risk factors associated with successful ablation in patients with DTC with CLNM who received 2 doses of 131I therapy. 131I administration is a useful therapy to eradicate cervical lymph node metastasis in patients with DTC, and may be preferentially indicated in patients with DTC with CLNM who are aged <45 years, with tumor sizes <2 cm, solitary nodules and lower TNM stages, in order to control and prevent recurrence and/or metastases.
Collapse
Affiliation(s)
- Chung-Jie Cao
- Department of Pathology, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong 510080, P.R. China
| | - Cheng-Yun Dou
- Department of Hepatology, Qilu Hospital of Shandong University, Jinan, Shandong 250012, P.R. China
| | - Jiayan Lian
- Department of Pathology, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong 510080, P.R. China
| | - Zhao-Sheng Luan
- Department of Nuclear Medicine, PLA 88 Hospital, Taian, Shandong 271000, P.R. China
| | - Wen Zhou
- Department of Nuclear Medicine, PLA 88 Hospital, Taian, Shandong 271000, P.R. China
| | - Wenlin Xie
- Department of Pathology, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong 510080, P.R. China
| | - Li Chen
- Department of Endocrinology, Qilu Hospital of Shandong University, Jinan, Shandong 250012, P.R. China
| | - Kehua Zhou
- Department of Endocrinology, Qilu Hospital of Shandong University, Jinan, Shandong 250012, P.R. China
| | - Hong Lai
- Department of Endocrinology, Qilu Hospital of Shandong University, Jinan, Shandong 250012, P.R. China
| |
Collapse
|
5
|
Gillanders SL, O'Neill JP. Prognostic markers in well differentiated papillary and follicular thyroid cancer (WDTC). Eur J Surg Oncol 2017; 44:286-296. [PMID: 28801060 DOI: 10.1016/j.ejso.2017.07.013] [Citation(s) in RCA: 38] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/01/2016] [Revised: 07/13/2017] [Accepted: 07/23/2017] [Indexed: 12/22/2022] Open
Abstract
OBJECTIVES WDTC (papillary and follicular thyroid cancer) make up around 90% of all thyroid tumours. Overall, the prognosis in patients with WDTC is excellent. However, there are small cohorts of patients who experience a more aggressive form of disease which is often associated with certain poor prognostic factors. Identifying these patients at an early stage is imperative for guiding treatment decisions. With recent developments in this area we plan to discuss the current evidence surrounding prognostic markers. METHODS The literature regarding prognostic factors in WDTC was reviewed using an electronic database Medline - Pubmed. Using the MeSH search engine specific prognostic factors including age, size, grade, lymph node involvement, distant metastasis, extension/invasion, ethnic background, radioactive iodine avidity, and thyroglobulin level and their association with WDTC were evaluated. A broader search of prognostic markers in thyroid cancer was also carried out to avoid missing other pertinent markers. RESULTS Multiple clinical and pathologic variables have been shown to be poor prognostic factors in WDTC with statistical significance. Extensive extrathyroidal extension and age may be the most important factors when predicting clinical outcomes in WDTC, although the age threshold may be increased from 45 to 55 years in due course. CONCLUSIONS Management of WDTC has changed considerably over the last two years as reflected in evolving British and American Thyroid Guidelines. In all cases a combined multi-disciplinary approach, with consideration of the available guidelines and stratification systems should be utilised when planning an individualised treatment program to offer the best contemporary care to WDTC patients.
Collapse
Affiliation(s)
- S L Gillanders
- Department of Otolaryngology, Head and Neck Surgery, Beaumont Hospital, The Royal College of Surgeons in Ireland, Ireland.
| | - J P O'Neill
- Department of Otolaryngology, Head and Neck Surgery, Beaumont Hospital, The Royal College of Surgeons in Ireland, Ireland
| |
Collapse
|
6
|
Furtado MDS, Rosario PW, Calsolari MR. Persistent and recurrent disease in patients with papillary thyroid carcinoma with clinically apparent (cN1), but not extensive, lymph node involvement and without other factors for poor prognosis. ARCHIVES OF ENDOCRINOLOGY AND METABOLISM 2017; 59:285-91. [PMID: 26331314 DOI: 10.1590/2359-3997000000081] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/06/2015] [Accepted: 05/11/2015] [Indexed: 11/22/2022]
Abstract
OBJECTIVE Lymph node metastases (LNM) are frequent in patients with papillary thyroid cancer (PTC). The risk of persistent disease (PD) and tumor recurrence (TR) is increased when factors for poor prognosis other than LNM exist, when LNM are numerous, large, detected by preoperative ultrasonography (US), or exhibit extranodal extension. This study evaluated the risk of PD and TR in patients with LNM not exhibiting these characteristics. SUBJECTS AND METHODS Eighty-six patients with 5 or fewer LNM detected during intraoperative inspection, but not by preoperative US, who had no other factors for poor prognosis [tumors > 4 cm, extensive extrathyroid invasion, vascular invasion, aggressive histological subtype, distant metastases, incomplete tumor resection], were studied. All patients underwent total thyroidectomy followed by radioiodine ablation. PD was defined as metastases on initial post-therapy whole-body scans (RxWBS) or detected by imaging methods up to 12 months after ablation. TR was defined as structural disease diagnosed more than one year after ablation in patients without PD. RESULTS PD was diagnosed in 3/86 patients (3.5%). TR was observed in 2/83 patients (2.5%) after 62 months of follow-up. There was no case of death due to the disease. A correlation was observed between pre-ablation Tg and PD or TR [1/48 (2%) with Tg ≤ 2 ng/mL versus 2/22 (9%) with Tg > 2 ≤ 10 ng/mL versus 2/7 (28.5%) with Tg ≥ 10 ng/ml)]. It is noteworthy that 38 patients had up to 3 positive LN and pre-ablation Tg ≤ 2 ng/ml, and none of them had PD or TR. CONCLUSIONS The frequency of PD and TR was low in patients with PTC with 5 or fewer LNM and without other factors for poor prognosis. Low postoperative stimulated Tg was predictive of the absence of PD and TR in these patients.
Collapse
|
7
|
Effects of long non-coding RNA H19 and microRNA let7a expression on thyroid cancer prognosis. Exp Mol Pathol 2017; 103:71-77. [PMID: 28655518 DOI: 10.1016/j.yexmp.2017.06.004] [Citation(s) in RCA: 29] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/12/2016] [Revised: 06/22/2017] [Accepted: 06/23/2017] [Indexed: 12/12/2022]
Abstract
This study aims to explore the effects of long non-coding RNA H19 (lncRNA H19) and microRNA let7a (miRNA let7a) expression on the prognosis of thyroid cancer (TC). This may aid in the discovery of more effective treatment and prognosis approaches for TC. Between January 2008 and January 2011, 131 TC tissues and adjacent tissues were obtained from TC patients. An additional 122 normal thyroid tissues were also collected as normal controls from patients with benign thyroid lesions. Quantitative real-time polymerase chain reaction (qRT-PCR) was used to detect lncRNA H19 and miRNA let7a mRNA expression. Five-year follow-ups were conducted. A Receiver operating characteristic (ROC) curve was used to evaluate the diagnostic values of lncRNA H19 and miRNA let7a in TC. The Kaplan-Meier method was applied to analyze the 5-year survival rate of TC patients. Univariate and multivariate factor analyses were employed to analyze the prognostic factors of TC. The lncRNA H19 mRNA expression was higher while the miRNA let7a mRNA expression was lower in TC tissues than, in the normal thyroid tissues and adjacent tissues. The area under the ROC curve (AUC) of lncRNA H19 and miRNA let7a were 0.801 and 0.116, with sensitivity at 72.5% and 84%, as well as specificity 75.4% and 77%, respectively. In TC patients with tumor diameters≥1.0cm, lncRNA H19 mRNA expression was elevated, but miRNA let7a mRNA expression was reduced. This was also evident in TC patients with TNM stages III+IV and those with lymph node metastasis. TC patients with a lower 5-year survival rate showed upregulated levels of lncRNA H19 expression and, downregulated levels of miRNA let7a expression. LncRNA H19 and miRNA let7a expression, tumor diameter, TNM stage and lymph node metastasis were independent prognostic factors of TC. This study demonstrated that increased lncRNA H19 and decreased miRNA let7a expression levels are associated with poor prognosis in TC patients. An inverse relationship between lncRNA H19 and miRNA let7a expression levels was exhibited.
Collapse
|
8
|
He LY, Wang WW, Ibrahima BA, Han S, Li Z, Cai Z, Chen ML, Chen BZ, Tan HS, Zeng HS, Dai XL, Zhou MW, Zhang GQ, Li GX. The prognostic value of regional lymph node metastases in patients of Guangdong Province, China with differentiated thyroid cancer: A multicenter retrospective clinical study. Medicine (Baltimore) 2016; 95:e5034. [PMID: 27741112 PMCID: PMC5072939 DOI: 10.1097/md.0000000000005034] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/14/2022] Open
Abstract
Although the prognostic value of nodal metastases in differentiated thyroid cancer remains controversial, it is of interest to evaluate and understand the different characteristics of predictive outcomes.A multicenter retrospective study was conducted in 215 untreated patients with differentiated thyroid cancer from July 1997 to July 2015 in 4 medical centers of Guangdong Province. A total of 107 patients with nodal metastases (group A) were compared to 108 patients without metastases (group B). The 5-year disease-free survival (DFS), overall survival (OS), and postoperative complications in both groups were calculated. Variables predictive of DFS and OS were evaluated in group A.The group A had lower 5-year DFS (69.16%, 11 months) and shorter median time of recurrence than those in group B (87.96%, 8.5 months, respectively, P < 0.001). The incidence of temporary hypoparathyroidism in group A is lower; whereas higher incidence of temporary unilateral vocal cord palsy, permanent hypoparathyroidism, permanent unilateral vocal cord palsy, and bilateral vocal cord palsy in group A were observed. Both univariate and multivariate analyses in group A revealed that age, pathological tumor node metastasis (pTNM) stage, and histology were related to DFS (P < 0.05); while pTNM stage and histology were related to OS only in univariate analyses.Positive nodal metastases have significant prognostic value in patients with differentiated thyroid cancer in Guangdong, China and primarily reduce DFS. Moreover, patients with positive nodal metastases who are >45 years and have higher pTNM stage or follicular histology tend to have poor prognosis. Selective lymph node dissection with appropriate postoperative treatment and frequent follow-up should be accorded to these vulnerable groups of patients.
Collapse
Affiliation(s)
- Lin-yun He
- Department of General surgery, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong Province, China
| | - Wei-wei Wang
- Department of General surgery, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong Province, China
| | - Balde Alpha Ibrahima
- Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong Province, China
| | - Shuai Han
- Department of General surgery, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong Province, China
| | - Zhou Li
- Department of General surgery, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong Province, China
- Correspondence: Zhou Li, Department of General Surgery, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong Province, China (e-mail: )
| | - Zhai Cai
- Department of General surgery, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong Province, China
| | - Miao-liang Chen
- Department of General surgery, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong Province, China
| | - Bao-zhu Chen
- Department of General surgery, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong Province, China
| | - Hui-shi Tan
- Department of General surgery, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong Province, China
| | - Hai-shan Zeng
- Department of General surgery, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong Province, China
| | - Xiao-li Dai
- Department of General surgery, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong Province, China
| | - Min-wei Zhou
- General Hospital of Guangzhou Military Command of PLA
| | - Gang-qing Zhang
- Guangdong No. 2 Provincial People's Hospital, Guangzhou, Guangdong Province, China
| | - Guo-xin Li
- Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong Province, China
| |
Collapse
|
9
|
Lamartina L, Grani G, Biffoni M, Giacomelli L, Costante G, Lupo S, Maranghi M, Plasmati K, Sponziello M, Trulli F, Verrienti A, Filetti S, Durante C. Risk Stratification of Neck Lesions Detected Sonographically During the Follow-Up of Differentiated Thyroid Cancer. J Clin Endocrinol Metab 2016; 101:3036-44. [PMID: 27186860 DOI: 10.1210/jc.2016-1440] [Citation(s) in RCA: 40] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/13/2023]
Abstract
CONTEXT The European Thyroid Association (ETA) has classified posttreatment cervical ultrasound findings in thyroid cancer patients based on their association with disease persistence/recurrence. OBJECTIVE The objective of the study was to assess this classification's ability to predict the growth and persistence of such lesions during active posttreatment surveillance of patients with differentiated thyroid cancer (DTC). DESIGN This was a retrospective, observational study. SETTING The study was conducted at a thyroid cancer center in a large Italian teaching hospital. PATIENTS Center referrals (2005-2014) were reviewed and patients selected with pathologically-confirmed DTC; total thyroidectomy, with or without neck dissection and/or radioiodine remnant ablation; abnormal findings on two or more consecutive posttreatment neck sonograms; and subsequent follow-up consisting of active surveillance. Baseline ultrasound abnormalities (thyroid bed masses, lymph nodes) were classified according to the ETA system. Patients were divided into group S (those with one or more lesions classified as suspicious) and group I (indeterminate lesions only). We recorded baseline and follow-up clinical data through June 30, 2015. MAIN OUTCOMES The main outcomes were patients with growth (>3 mm, largest diameter) of one or more lesions during follow-up and patients with one or more persistent lesions at the final visit. RESULTS The cohort included 58 of the 637 DTC cases screened (9%). A total of 113 lesions were followed up (18 thyroid bed masses, 95 lymph nodes). During surveillance (median 3.7 y), group I had significantly lower rates than group S of lesion growth (8% vs 36%, P = .01) and persistence (64% vs 97%, P = .014). The median time to scan normalization was 2.9 years. CONCLUSIONS The ETA's evidence-based classification of sonographically detected neck abnormalities can help identify papillary thyroid cancer patients eligible for more relaxed follow-up.
Collapse
Affiliation(s)
- Livia Lamartina
- Dipartimento di Medicina Interna e Specialità Mediche (L.L., G.G., S.L., M.M., K.P., M.S., F.T., A.V., S.F., C.D.), Dipartimento di Scienze Chirurgiche (M.B., L.G.), Università di Roma "Sapienza," 00161 Roma, Italy; and Department of Internal Medicine (G.C.), Institut Jules Bordet Comprehensive Cancer Center, 1000 Brussels, Belgium
| | - Giorgio Grani
- Dipartimento di Medicina Interna e Specialità Mediche (L.L., G.G., S.L., M.M., K.P., M.S., F.T., A.V., S.F., C.D.), Dipartimento di Scienze Chirurgiche (M.B., L.G.), Università di Roma "Sapienza," 00161 Roma, Italy; and Department of Internal Medicine (G.C.), Institut Jules Bordet Comprehensive Cancer Center, 1000 Brussels, Belgium
| | - Marco Biffoni
- Dipartimento di Medicina Interna e Specialità Mediche (L.L., G.G., S.L., M.M., K.P., M.S., F.T., A.V., S.F., C.D.), Dipartimento di Scienze Chirurgiche (M.B., L.G.), Università di Roma "Sapienza," 00161 Roma, Italy; and Department of Internal Medicine (G.C.), Institut Jules Bordet Comprehensive Cancer Center, 1000 Brussels, Belgium
| | - Laura Giacomelli
- Dipartimento di Medicina Interna e Specialità Mediche (L.L., G.G., S.L., M.M., K.P., M.S., F.T., A.V., S.F., C.D.), Dipartimento di Scienze Chirurgiche (M.B., L.G.), Università di Roma "Sapienza," 00161 Roma, Italy; and Department of Internal Medicine (G.C.), Institut Jules Bordet Comprehensive Cancer Center, 1000 Brussels, Belgium
| | - Giuseppe Costante
- Dipartimento di Medicina Interna e Specialità Mediche (L.L., G.G., S.L., M.M., K.P., M.S., F.T., A.V., S.F., C.D.), Dipartimento di Scienze Chirurgiche (M.B., L.G.), Università di Roma "Sapienza," 00161 Roma, Italy; and Department of Internal Medicine (G.C.), Institut Jules Bordet Comprehensive Cancer Center, 1000 Brussels, Belgium
| | - Stefania Lupo
- Dipartimento di Medicina Interna e Specialità Mediche (L.L., G.G., S.L., M.M., K.P., M.S., F.T., A.V., S.F., C.D.), Dipartimento di Scienze Chirurgiche (M.B., L.G.), Università di Roma "Sapienza," 00161 Roma, Italy; and Department of Internal Medicine (G.C.), Institut Jules Bordet Comprehensive Cancer Center, 1000 Brussels, Belgium
| | - Marianna Maranghi
- Dipartimento di Medicina Interna e Specialità Mediche (L.L., G.G., S.L., M.M., K.P., M.S., F.T., A.V., S.F., C.D.), Dipartimento di Scienze Chirurgiche (M.B., L.G.), Università di Roma "Sapienza," 00161 Roma, Italy; and Department of Internal Medicine (G.C.), Institut Jules Bordet Comprehensive Cancer Center, 1000 Brussels, Belgium
| | - Katia Plasmati
- Dipartimento di Medicina Interna e Specialità Mediche (L.L., G.G., S.L., M.M., K.P., M.S., F.T., A.V., S.F., C.D.), Dipartimento di Scienze Chirurgiche (M.B., L.G.), Università di Roma "Sapienza," 00161 Roma, Italy; and Department of Internal Medicine (G.C.), Institut Jules Bordet Comprehensive Cancer Center, 1000 Brussels, Belgium
| | - Marialuisa Sponziello
- Dipartimento di Medicina Interna e Specialità Mediche (L.L., G.G., S.L., M.M., K.P., M.S., F.T., A.V., S.F., C.D.), Dipartimento di Scienze Chirurgiche (M.B., L.G.), Università di Roma "Sapienza," 00161 Roma, Italy; and Department of Internal Medicine (G.C.), Institut Jules Bordet Comprehensive Cancer Center, 1000 Brussels, Belgium
| | - Fabiana Trulli
- Dipartimento di Medicina Interna e Specialità Mediche (L.L., G.G., S.L., M.M., K.P., M.S., F.T., A.V., S.F., C.D.), Dipartimento di Scienze Chirurgiche (M.B., L.G.), Università di Roma "Sapienza," 00161 Roma, Italy; and Department of Internal Medicine (G.C.), Institut Jules Bordet Comprehensive Cancer Center, 1000 Brussels, Belgium
| | - Antonella Verrienti
- Dipartimento di Medicina Interna e Specialità Mediche (L.L., G.G., S.L., M.M., K.P., M.S., F.T., A.V., S.F., C.D.), Dipartimento di Scienze Chirurgiche (M.B., L.G.), Università di Roma "Sapienza," 00161 Roma, Italy; and Department of Internal Medicine (G.C.), Institut Jules Bordet Comprehensive Cancer Center, 1000 Brussels, Belgium
| | - Sebastiano Filetti
- Dipartimento di Medicina Interna e Specialità Mediche (L.L., G.G., S.L., M.M., K.P., M.S., F.T., A.V., S.F., C.D.), Dipartimento di Scienze Chirurgiche (M.B., L.G.), Università di Roma "Sapienza," 00161 Roma, Italy; and Department of Internal Medicine (G.C.), Institut Jules Bordet Comprehensive Cancer Center, 1000 Brussels, Belgium
| | - Cosimo Durante
- Dipartimento di Medicina Interna e Specialità Mediche (L.L., G.G., S.L., M.M., K.P., M.S., F.T., A.V., S.F., C.D.), Dipartimento di Scienze Chirurgiche (M.B., L.G.), Università di Roma "Sapienza," 00161 Roma, Italy; and Department of Internal Medicine (G.C.), Institut Jules Bordet Comprehensive Cancer Center, 1000 Brussels, Belgium
| |
Collapse
|
10
|
Veronese N, Luchini C, Nottegar A, Kaneko T, Sergi G, Manzato E, Solmi M, Scarpa A. Prognostic impact of extra-nodal extension in thyroid cancer: A meta-analysis. J Surg Oncol 2015; 112:828-33. [DOI: 10.1002/jso.24070] [Citation(s) in RCA: 38] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/15/2015] [Accepted: 10/01/2015] [Indexed: 12/15/2022]
Affiliation(s)
- Nicola Veronese
- Geriatrics Division; Department of Medicine; University of Padova; Padova Italy
| | - Claudio Luchini
- Department of Pathology and Diagnostics; University and Hospital Trust of Verona; Verona Italy
| | - Alessia Nottegar
- Department of Pathology and Diagnostics; University and Hospital Trust of Verona; Verona Italy
| | - Takuma Kaneko
- Department of Molecular Pathology; Tohoku University School of Medicine; Sendai Japan
| | - Giuseppe Sergi
- Geriatrics Division; Department of Medicine; University of Padova; Padova Italy
| | - Enzo Manzato
- Geriatrics Division; Department of Medicine; University of Padova; Padova Italy
| | - Marco Solmi
- Department of Neurosciences; University of Padova; Padova Italy
| | - Aldo Scarpa
- Department of Pathology and Diagnostics; University and Hospital Trust of Verona; Verona Italy
| |
Collapse
|
11
|
P53 and expression of immunological markers may identify early stage thyroid tumors. Clin Dev Immunol 2013; 2013:846584. [PMID: 24171036 PMCID: PMC3792533 DOI: 10.1155/2013/846584] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/18/2013] [Accepted: 08/20/2013] [Indexed: 02/07/2023]
Abstract
Background. Besides its major role in cell proliferation, DNA repair, and apoptosis, functional p53 protein is involved in the induction of antitumor cytotoxic-T-cell activity against carcinoma cells. We aimed to investigate p53 and immune cell markers utility as diagnostic and prognostic markers of differentiated thyroid cancer (DTC). Methods. ACIS-III system was used to evaluate p53 and immune cell markers including tumor-associated macrophages (TAM); CD68 and tumor-infiltrating lymphocytes (TIL) subsets such as CD3, CD4, CD8, and CD20 in 206 thyroid carcinomas, 105 benign nodules, and 18 normal tissues. Also, TP53 was sequenced in 78 out of 164 patients with papillary thyroid carcinoma. Results. P53 expression was observed more frequently in malignant than in benign lesions (P < 0.0001) and helped discriminate follicular patterned lesions. In addition, p53 was more frequent in smaller (P = 0.0015), unique tumors (P = 0.0286), with thyroiditis (P = 0.0486) and without metastasis at diagnosis (P = 0.0201). TAM was more frequent in P53 negative tumors (P = 0.002). Infiltration of CD8+ TIL was found in 61.7% of P53 positive and 25.6% of P53 negative DTC (P < 0.001). Conclusions. We suggest that p53 and CD8+ TIL immune profile analysis might be useful in DTC.
Collapse
|